---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-169756"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:01:38.230303+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cogent reaches FDA alignment on MS2D2 endpoint for SUMMIT trial; enrollment timeline reaffirmed

## Summary
- FDA alignment on novel patient-reported outcome measure MS2D2 for Part 2 of SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM).
- SUMMIT Part 2 enrollment on track to complete Q2 2025; top-line results expected by end of 2025.
- APEX study (Advanced SM) enrollment to complete end of 2024; top-line results mid-2025.
- PEAK study (GIST) enrollment expected to complete Q3 2024; top-line results by end of 2025.

## SEC filing metadata
- accession: 0001193125-24-169756
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312524169756/0001193125-24-169756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312524169756/d792910d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-169756
- JSON: https://secwatch.observer/filing/0001193125-24-169756.json
- Plain text: https://secwatch.observer/filing/0001193125-24-169756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.